Stock GILD34 GILEAD SCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Gilead Sciences, Inc. Sao Paulo

Equities

GILD34

BRGILDBDR000

Market Closed - Sao Paulo
Other stock markets
 15:27:01 28/06/2024 BST 		5-day change 1st Jan Change
191.4 BRL +11.35% Intraday chart for Gilead Sciences, Inc. +0.55% -0.57%
06-27 Gilead Sciences, Inc Announces New Data Support the Use of BICtegravir Tablet Regimen to Treat People with HIV and Individuals with HIV/HBV-Coinfection in Asia CI
06-26 Redburn Atlantic Adjusts Price Target on Gilead Sciences to $119 From $117 MT

Summary

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • Given the positive cash flows generated by its business, the company's valuation level is an asset.
  • The company is one of the best yield companies with high dividend expectations.

Weaknesses

  • As estimated by analysts, this group is among those businesses with the lowest growth prospects.
  • With an expected P/E ratio at 200.68 and 13.27 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • The company's enterprise value to sales, at 3.76 times its current sales, is high.
  • The company appears highly valued given the size of its balance sheet.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
GILEAD SCIENCES, INC. Stock Gilead Sciences, Inc.
-0.57% 85.48B -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+55.32% 815B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+44.05% 641B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.75% 352B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+13.56% 314B
B-
ABBVIE INC. Stock AbbVie Inc.
+10.68% 303B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.57% 242B
B+
NOVARTIS AG Stock Novartis AG
+13.31% 218B
B-
AMGEN INC. Stock Amgen Inc.
+8.48% 168B
C+
PFIZER, INC. Stock Pfizer, Inc.
-2.81% 159B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. GILD Stock
  4. GILD34 Stock
  5. Ratings Gilead Sciences, Inc.